Study to Assess Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Overview

About this study

The purose of this study is to assess the effectiveness and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE) decompensation in liver cirrhosis, defined by the presence of medically controlled ascites.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Key Inclusion Criteria:

- Diagnosis of liver cirrhosis with medically controlled ascites (> 30 days) not
requiring therapeutic paracentesis (could have had paracentesis in the past).

- Conn (West Haven Criteria) score of < 2.

- Mini-Mental State Examination (MMSE) score > 24 at screening.

- ≥ 18 and ≤ 85 years of age.

Key Exclusion Criteria:

- Active COVID-19 that is unresolved

- History of SBP

- History of EVB or AKI-HRS within 6 months

- History of OHE episode (Conn score ≥ 2)

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 4/18/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Manal Abdelmalek, M.D.

Closed for enrollment

Contact information:

Marina Takawy M.B., B.Ch.

(507) 293-0913

Takawy.Marina@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20554548

Mayo Clinic Footer